Pipeline by indication

NETRIS Pharma is conducting a large Clinical Development Plan with its lead asset NP137. A pipeline of new products targeting other ligands is also in construction.

Image-pipeline

Pipeline

Program Target Indication Discovery IND Enabling Phase I Phase II Late-Stage Development
NP137 + Pembro(*)/Carbotaxol
Netrin-1

Endometrium / Cervix
NP137 + Approved Immune Checkpoint
Netrin-1

Basket: • NSLCC
• Head & Neck
• Melanoma
NP137 + Atezo-Bev
Netrin-1

Liver
NP137 + Folfirinox
Netrin-1

Pancreas – Locally advanced
NP137 + Folfirinox
Netrin-1

Pancreas – Resectable
NP137P
Netrin-1

Endometriosis
NP137R
Netrin-1

Netrin-1 expressing cancer (radiotherapy)
NP800
Undisclosed target

Glioblastoma
(*) In combination with Pembrolizumab, provided through a clinical trial collaboration and supply agreement with Merck & Co. Inc., Kenilworth, NJ, USA.

Clinical Development

NETRIS Pharma's clinical development plan encompasses five recruiting clinical trials aimed at confirming the ability of its lead asset, NP137, to reduce tumors growth and aggressiveness as well as to overcome resistance to current standard of care. Through its long-term collaboration with the Leon Bérard Comprehensive Cancer Center, NETRIS Pharma accesses a unique set of multidisciplinary technological platforms to conduct ambitious ancillary research programs to identify relevant biomarkers and better characterize patients who shall most likely benefit from the treatment.

Image-formes
6-layers

Get in touch

Contact us